These considerations, however, are complicated by our finding that CT-X expression is not limited to the TN BLC group, as a fraction of CT-X expressing HR− tumors in this study were positive for HER2, whose over-expression identifies a subgroup of BC with molecular characteristics distinct from BLC [15]. The gene discussed is CYP27A1; the disease is breast cancer.